Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

T-DM1 Demonstrates Overall Survival Benefit in Metastatic Breast Cancer

Published: Thursday, August 30, 2012
Last Updated: Wednesday, August 29, 2012
Bookmark and Share
Next target, FDA approval.

In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab emtansine) offers a “significant” overall survival increase to patients with metastatic breast cancer compared to the combination of GSK’s Tykerb (lapatinib) and Roche/Genentech’s Xeloda (capecitabine).

This is the latest data from the 991-person, randomized, open-label Phase III EMILIA study, which compared the efficacy of T-DM1 to the Tykerb/Xeloda combination in patients with HER2-positive locally advanced or metastatic breast cancer previously treated with Herceptin and chemotherapy.

While a trend suggesting an overall survival (OS) increase as well as clear improvement in progression-free survival (PFS) was presented at the 2012 annual meeting of the American Society of Clinical Oncology, this definitive OS benefit will greatly facilitate T-DM1’s regulatory approval.

PFS and OS were the co-primary endpoints of the EMILIA trial, both of which now have been met. The companies have not revealed the extent of the OS increase, only that it was “significant”, meaning that the improvement exceeded a pre-specified boundary.

Following the results of this analysis, EMILIA patients taking Tykerb/Xeloda will be offered the option to switch to T-DM1, and the companies are planning to initiate an Expanded Access Program in the US so that certain patients in dire need can have access to the drug.

T-DM1 is a next generation antibody-drug conjugate (ADC) that has garnered ample media attention over the last year. The basic concept of an ADC is to use an antibody that binds to a cancer-specific marker to deliver a cytotoxic agent directly to cancer cells.

By targeting the toxic compounds specifically to the cancerous cells, lower doses can be used, and the overall safety profile of a cytotoxic drug will theoretically improve compared to non-targeted therapy.

T-DM1 adds another benefit, as the cytotoxic compound, Immunogen’s DM-1, is linked with the company’s Targeted Antibody Payload technology (TAP) to Roche/Genentech’s blockbuster therapeutic antibody Herceptin (trastuzumab).

Herceptin not only targets DM1 to HER2-positive breast cancer cells, but acts as a targeted anti-cancer agent in its own right by blocking HER2 signaling and mediating the immune system’s clearance of HER2-positive cells.

Therefore T-DM1 should be more effective and better tolerated than first generation ADCs, and this positive OS data is proof of concept, representing a major advance in targeted drug development.

Genentech has announced that it has filed a Biologics License Application (BLA) to the FDA in the US, and Roche is planning to submit a Marketing Authorization Application to the European Medicines Agency in the near future.

The companies’ first attempt at gaining regulatory approval fell flat in 2010, when the FDA refused to file Roche’s application for accelerated approval of T-DM1.

The initial application was based on results from a single-arm Phase II study showing that the drug shrank tumors in women with advanced HER2-positive breast cancer.

With T-DM1 now demonstrating both OS and PFS benefits, as well as a more tolerable safety profile compared to Tykerb/Xeloda, the drug is expected to breeze through the approval process. US approval could come as early as Q2 2013, although EMA approval is unlikely before Q4 2013.

The companies will initially seek approval of T-DM1 as a treatment for patients with metastatic breast cancer who have previously been treated with multiple lines of therapy, but that is only the beginning of the companies’ plan for the drug.

The Phase III MARIANNE trial has completed enrollment, and is intended to provide data to support the regulatory filing of T-DM1 as a first-line treatment for HER2-positive metastatic breast cancer.

Additionally, the companies are exploring the benefits of T-DM1 in combination with Roche/Genentech’s Perjeta (pertuzumab) in patients with HER2-positive locally advanced or metastatic breast cancer.

Roche and Genentech hope that eventually T-DM1 will infiltrate the early stage HER2-positive breast cancer treatment algorithm, as the majority of patients are diagnosed with localized disease.

In June, Roche announced plans to initiate three more T-DM1 trials in patients with early disease, evaluating the drug for neoadjuvant use, adjuvant use, and to treat recurrent disease following surgery within this patient segment.

If all goes as planned, T-DM1 should be able to replace Herceptin in the majority of breast cancer patient segments in which Herceptin is currently used.

Given the potential breadth of use, the high prevalence of breast cancer and the fact that T-DM1 (similarly to Perjeta) will be priced at a premium to Herceptin, T-DM1 undoubtedly has blockbuster potential.

This is good news for Roche/Genentech, as their top-selling product Herceptin, with sales grossing over $3 billion in 2012 H1, will be facing generic competition following patent expiry in 2015.

Immunogen also stands to reap rewards from T-DM1’s success, as the company will collect mid-single-digit royalties on the sales.

This will help fund the clinical development of IMGN901, Immunogen’s lead wholly-owned compound, for the first-line treatment of small-cell lung cancer and for relapsed multiple myeloma.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promising Malaria and Dengue Vaccines Will Not Defeat Diseases
Although vaccination is a key part of the control of disease GlobalData stress the importance of a multi-dimensional approach.
Friday, May 22, 2015
The Fall from Grace of Peregrine Pharmaceuticals
On September 24, 2012, the company announced the discovery of ‘major data discrepancies’ between reported results and patient treatment code assignments.
Wednesday, October 17, 2012
The World’s First (Official) Biosimilar Antibody Goes to… Rheumatoid Arthritis
Remsima is the first officially approved biosimilar antibody for RA therapy.
Thursday, August 09, 2012
The World’s First (Official) Biosimilar Antibody Goes to… Rheumatoid Arthritis
Celltrion announces the approval of Remsima (CT-P13), a biosimilar antibody, by the Korean Food and Drug Administration.
Wednesday, August 08, 2012
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos